Clin Gastroenterology H: Analysis of the role of tumor necrosis pathogen antagonists in patients with primary sclerotic bileitis.

Primary sclerosis bileitis (PSC) is an idioid and heterogeneous liver and bile disease characterized by advanced bile tube inflammation and fibrosis, which eventually causes bile depression.
pathogenesis of primary sclerosis bileitis is not clear, there is no clinically effective treatment, a small number of patients can survive liver transplantation.
And PSC combined with inflammatory bowel disease (IBD) patients are rare, IBD patients often use anti-tumor necrosis caused by the treatment, then the role of anti-tumor necrosis in PSC has not been reported, this study is intended to carry out related research.
the researchers conducted retrospective analyses of 141 PSC and IBD patients treated with anti-tumor necrotic cause (TNF) (Invlixi monoantigen or Adamo monoantigen).
collected and measured their serum alkaline phosphatase (ALP) levels.
the IBD obtained is defined as an endoscopic reaction or a clinical response.
to use linear regression analysis to determine factors significantly related to ALP levels during anti-TNF therapy.
results showed that anti-TNF therapy had a remission response in 48% of IBD patients.
no difference in the rate of PSC symptoms before or after drug exposure.
most common causes of deactivation of anti-TNF are IBD primary non-reactive (17%) and side effects (18%).
at 3 months, the median serum ALP in patients treated with Invlixi monoantigen decreased by 4%, compared with a 15% decrease in patients treated with adamu monoantigen (P.035).
factors associated with lower ALP are normal ALP at baseline (P .lt;.01).
(Adamu monoantigen effect is better) This study reviewed 141 PSC and IBD patients and found that anti-TNF drugs were moderately effective and were not associated with increased PSC symptoms or specific side effects.
but the use of adamo monoantigen and serum ALP reduction are predictive factors for the cool-back prognosis.
.